Targets › SLC11A2
3 programs from 3 companies in 14 trials: 7 Phase 4, 5 Phase 3, 2 Phase 2; Hematology, Cardiovascular, Oncology; next expected readout Dec 2026.
Proton-coupled metal ion symporter operating with a proton to metal ion stoichiometry of 1:1. Selectively transports various divalent metal cations, in decreasing affinity: Cd(2+) > Fe(2+) > Co(2+), Mn(2+) >> Zn(2+), Ni(2+), VO(2+). (UniProt, P49281)
Open in Phaseline: the race on SLC11A2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Pharmacosmos | Ferric Derisomaltose Iron delivery via carbohydrate complex; replenishes iron stores in iron-deficiency anemia | SLC11A2 | Phase 3 | Iron Deficiency, Anaemia in Children; Chronic Heart Failure; Perioperative Anemia; Iron Deficiency Anemia … | Apr 2027 |
| Vanderbilt University Medical Center | Intravenous iron Iron supplementation to restore iron stores | SLC11A2 | Phase 2 | POTS - Postural Orthostatic Tachycardia Syndrome | Dec 2026 |
| Fox Chase Cancer Center | Venofer (iron sucrose) Iron replacement therapy | SLC11A2 | Phase 2 | Anemia | Feb 2027 |
Iron Deficiency Anemia (2) Anemia (1) Iron Deficiency, Anaemia in Children (1) Chronic Heart Failure (1) Perioperative Anemia (1) Hip Fracture (1) Heart Failure With Reduced Ejection Fraction (1) Heart Failure With Preserved Ejection Fraction (1) Heart Failure (1) IDA - Iron Deficiency Anemia (1) Anemia, Iron Deficiency (1) Gynecologic Cancer (1)
small molecule (3)
Fox Chase Cancer Center (1) Pharmacosmos (1) Vanderbilt University Medical Center (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.